Crestone Pharma

Crestone is a Boulder, Colorado based clinical stage biopharmaceutical company developing new drug candidates with entirely novel mechanisms. Our research pipeline includes C. diff treatment, antibiotic-resistant Gram-positive infection treatments, Tuberculosis treatments, and more.

Crestone is a team of scientists with experience in the areas of synthetic organic chemistry, process chemistry, analytical chemistry, microbiology, cell biology, biochemistry, and pharmacology. As one of the leading research pharmaceutical companies in Colorado, we take a team-based approach to solving challenging problems and are passionate about making a real difference with our work.

We are developing a novel class of small molecule antibiotics targeting PolC, the replicative DNA polymerase in Gram-positive bacteria. By inhibiting a novel bacterial target, these compounds circumvent existing mechanisms of antibiotic resistance. CRS0540 exhibits broad spectrum activity against all clinically significant Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA), penicillin-resistant Streptococcus pneumoniae (PRSP), Streptococcus pyogenes (Group A strep), Streptococcus agalactiae (Group B strep), vancomycin-resistant Enterococci (VRE), Bacillus anthracis (anthrax), and Listeria monocytogenes.

CRS3123 is a small molecule protein synthesis inhibitor that acts on the novel target methionyl-tRNA synthetase (MetRS). CRS3123 has numerous potential advantages over current CDI therapies.

CRS3123 is a small molecule protein synthesis inhibitor that acts on the novel target methionyl-tRNA synthetase (MetRS). CRS3123 has numerous potential advantages over current CDI therapies.

Learn more about C. difficile Infection (CDI) and the Phase 2 study of CRS3123 here: https://bit.ly/3zhg5Kb

Antibiotics are powerful tools in our medical arsenal, but their misuse can lead to dire consequences.

This World Antibiotic Awareness Week, let's pledge to be stewards of our health and global well-being. Responsible antibiotic use is a small step for individuals, a giant leap for humanity.

Let's take a moment to express our heartfelt thanks to healthcare providers and clinical researchers for their unwavering dedication to finding solutions for infectious diseases.

Your tireless efforts save lives and inspire us all.

Remember that when facing health issues, your mental well-being matters too.

Reach out, seek support, and prioritize your mental health. You don't have to go through it alone. 💚

Clostridium difficile infection (CDI) is a gastrointestinal condition caused by toxin-producing strains of C. difficile bacteria. CDI symptoms range from severe diarrhea to toxic megacolon. C. difficile forms spores that are very difficult to eliminate from the hospital environment, leading to infection of hospitalized patients. Emergence of hypervirulent and drug-resistant strains of C. diff has resulted in an alarming increase in incidence and mortality of CDI in the past 15 years, especially among elderly patients.

At Crestone we are developing a novel class of small molecule antibiotics targeting PolC, the replicative DNA polymerase in Gram-positive bacteria. By inhibiting a novel bacterial target, these compounds circumvent existing mechanisms of antibiotic resistance.